MedTrace Logo

The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes

NCT07113730 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-08-15

No results posted yet for this study

Summary

Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment. Immune reconstitution (IR) is critical for improving HSCT efficacy and quality of life among survivors, yet its dynamic impact on survival and complications like chronic graft-versus-host disease (cGVHD) in CMML is poorly defined. This study aimed to investigate the dynamics of IR following HSCT in patients with CMML and evaluate its impact on post-transplant clinical outcomes.

Conditions

  • Chronic Myelomonocytic Leukemia (CMML)
  • Immune Reconstitution

Interventions

OTHER

immune reconstitution

Detection of immune reconstitution in peripheral blood of patients by flow cytometry at 30-day intervals for 180 days post-transplantation.

Sponsors & Collaborators

  • The First Hospital of Jilin University

    collaborator OTHER

  • the 960th Hospital of the People's Liberation Army Joint Logistics Support Force

    collaborator UNKNOWN

  • Shanghai General Hospital, ShanghaiJiao Tong University School of Medicine

    collaborator UNKNOWN

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Xiao-Hui Zhang, MD · Peking University Institute of Hematology, Peking University People's Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-13
Primary Completion
2035-07-31
Completion
2036-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07113730 on ClinicalTrials.gov